OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecast to 2025
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Endometriosis is an estrogen-dependent, chronic, inflammatory disease characterized by the appearance and growth of endometrial cells or tissues in locations outside the uterus. It is a common gynecological condition; however the disease is underdiagnosed due to the invasive nature of laparoscopy that confirms diagnosis. GlobalData estimates the endometriosis prevalence, including suspected and confirmed cases, to grow from 9.6 million to 11.3 million worldwide between 2015 and 2025. Current FDA-approved therapies for endometriosis comprise drugs that suppress ovulation and/or induce a hypoestrogenic state including gonadotrophin–releasing hormone (GnRH) analogues, progestins, and danazol. Off-label medical treatment for endometriosis, commonly prescribed before definitive diagnosis is made, include NSAIDs and hormonal contraceptives. The endometriosis market will undergo a moderate growth from 1.72 billion to reach sales of $2.04 billion over the 10-year period. This growth will primarily be driven by the increasing diagnosed endometriosis patients in the 7MM and the highly anticipated arrival of the novel GnRH antagonist, elagolix, due to be released in the US and 5EU in 2018. Nevertheless, patent expiries of some branded drugs and the sparsely populated endometriosis pipeline will curtail market growth during the forecast period.
Scope
Overview of endometriosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized endometriosis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the endometriosis therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
Oral contraceptives are among the market leaders for endometriosis, prescribed off-label as first-line of therapy to alleviate endometriosis-associated pain. Second-line therapies, such as GnRH agonists, are effective treatments; however their undesirable hypoestrogenic side effects and failure to prevent symptom recurrence limit their use. Another limitation of hormonal regimens is that their use prevents conception. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the endometriosis market?
The current late-stage endometriosis pipeline encompasses one novel therapeutic drug class, GnRH antagonists, of which elagolix will be the first to enter the market. Will the late-stage drugs make a significant impact on the endometriosis market? Will elagolix become the market leader over the 10-year forecast period, and why?
We have seen considerable efforts over the past years to raise awareness and to identify biomarkers for endometriosis. How will epidemiological changes impact the growth of the future market?
Bayer
Evotec
AbbVie
Nobelpharma
Takeda
Mochida
Abbott
Sanofi
AstraZeneca
Astellas Pharma
Ipsen
Ferring
Mitsubishi
Merck
Organon
Kissei
Teva
Barr Laboratories
Duramed Pharma
Resource Medical
Laboratory Biodim
Rottapharm SL
Repros
PregLem
Nobelpharma
Gedeon Richter
Euroscreen
GlaxoSmithKline
Nippon Shinyaku
SK Chemicals
Evestra
Forendo Pharma
ElexoPharm
Philogen
ValiRx
Viteava Pharma
Dongkook Pharma
Luye Pharma Group
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.